Antag Therapeutics to Unveil First-in-Human AT7687 Data as It Prepares Phase 2 Obesity Studies

New updates have been reported about Antag Therapeutics.

Antag Therapeutics will present first-in-human data on its lead GIP receptor antagonist AT7687 at the American Diabetes Association 2026 Scientific Sessions, underscoring clinical momentum behind its personalized obesity treatment strategy. The oral presentation will detail safety, tolerability, and pharmacologic data in healthy volunteers and people living with obesity, with results indicating AT7687 is well tolerated and suitable for once-weekly subcutaneous dosing.

In a separate poster, Antag will showcase preclinical data demonstrating that combining AT7687 with the dual amylin and calcitonin receptor agonist cagrilintide yields marked weight loss alongside substantial gains in insulin sensitivity and body composition in obese, insulin-resistant non-human primates, supporting a potential co-formulation strategy. These data, together with the recently completed Phase 1 trial and a planned Phase 2a program starting mid-2026, position Antag to compete in the next wave of obesity therapeutics, backed by a €80 million Series A round led by specialist life sciences investors and grounded in decades of metabolic research by GLP-1 pioneer Professor Jens Juul Holst.